Kaye-Eileen Willard, MD
Internal Medicine · Racine, WINPI 1841200383
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,584 of the $46,513 with a category attached, or 80.8%. 4 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 58.2% of the total. Reporting peaked in 2019 at $42,432 and has fallen 98.8% since, to $492 in 2025. Among internal medicine clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $762.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$27K
- Regeneron Healthcare Solutions, Inc.$10K
- Amgen$7K
- Akcea Therapeutics, Inc.$3K
What the payments were for
- Speaking & faculty fees$37,58481%
- Travel & lodging$6,94515%
- Food & beverage$1,9704%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 19 | $27,088 |
| Regeneron Healthcare Solutions, Inc. | 15 | $9,694 |
| Amgen | 18 | $6,895 |
| Akcea Therapeutics, Inc. | 9 | $2,835 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,513 in reported general payments places this provider in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 213 | $240,704 |
| Praluent PenAlirocumab | 106 | $142,599 |
| VascepaIcosapent Ethyl | 52 | $36,168 |
| NexletolBempedoic Acid | 15 | $15,799 |
| Icosapent Ethyl | 16 | $8,972 |
| Ezetimibe | 260 | $5,149 |
| Omega-3 Acid Ethyl Esters | 47 | $4,756 |
| Atorvastatin Calcium | 313 | $2,811 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 12 | $1,306 |
| FenofibrateFenofibrate Nanocrystallized | 37 | $881 |
| Rosuvastatin Calcium | 116 | $866 |
| Fenofibrate | 48 | $507 |
| Metformin Hcl ErMetformin Hcl | 13 | $283 |
| Pravastatin Sodium | 19 | $209 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Racine
- Jeremiah DeptaMilwaukee$723K
- James KuplicSheboygan$201K
- Erik StilpMilwaukee$116K
- Christopher WeberGermantown$113K
- Alejandro EismaWinnebago$84K
- Hammam ShereefMilwaukee$55K
- Brian SchreiberNeenah$49K
- Haroon ZubairWauwatosa$40K
- Mohammed PremjeeNew Berlin$38K
- Muhammad ZamanMilwaukee$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.